BioWorld

Feb. 9, 2006

Entereg’s Positive Phase III Data Drive Up Adolor’s Stock

Adolor Corp. unveiled positive Phase III data on Entereg (alvimopan), its partnered product for postoperative ileus, boosting shares in the company. (BioWorld Today) Read More

Immtech Prices $16M Public Offering; EpiCept Adds $11M

PDZ Binding Domain Origins Determinant Of Flu Severity

Optimized Proteases Garner $30M In Catalyst’s Series B

Oscient Gets Ramoplanin Rights Back From Pfizer

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

HMNC raises $50M series B to prep depression drugs for phase III

BioWorld

HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...